Small Molecules as Potent Protein Tyrosine Phosphatase 1B (PTP1B) Inhibitors Documented in Patents from 2009 to 2013

Author(s): Li-Jun Wang, Bo Jiang, Ning Wu, Shuai-Yu Wang, Da-Yong Shi

Journal Name: Mini-Reviews in Medicinal Chemistry

Volume 15 , Issue 2 , 2015

Become EABM
Become Reviewer
Call for Editor


Diabetes mellitus, including type 1 and type 2 diabetes mellitus (2-DM) are the main threats to human health in the worldwide. Protein tyrosine phosphatase 1B (PTP1B) is a promising molecular level legitimate therapeutic target in the effective management of 2-DM. For the search of potent PTP1B inhibitors, much investigation has revealed a large number of small-molecule compounds obtained from natural sources or prepared by synthesis/semi-synthesis with various skeletons and promising anti-PTP1B activities in the treatment of 2-DM. Although some reviews on the development of PTP1B inhibitors have been published, they were mainly concentrated on the results reported in journal articles. In this review, we will provide an overview of the developments of the potent PTP1B inhibitors claimed in recent patents during the past five years (2009-2013) with their structural features and biological features, as well as the structure-activity relationships (SARs) and strategies for finding potent and specific PTP1B inhibitors. This paper will provide valuable information for understanding the current anti-PTP1B investigation and developing potent PTP1B inhibitors as treating 2-DM drugs.

Keywords: Chemical modification, diabetes mellitus, natural products, patents, PTP1B inhibitors, synthesized compounds, type 2 diabetes mellitus (2-DM).

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 05 March, 2015
Page: [104 - 122]
Pages: 19
DOI: 10.2174/1389557515666150203144339
Price: $65

Article Metrics

PDF: 65
PRC: 1